Dexrazoxane Not Associated with Late Mortality in Pediatric Patients
the Cancer Therapy Advisor take:
After extended follow-up, dexrazoxane treatment did not seem to compromise overall survival among pediatric patients with leukemia or lymphoma, according to a report from the Children’s Oncology Group and published online this week in the Journal of Clinical Oncology.
The three clinical trials conducted over a 5-year period were P9404 (T-cell acute lymphoblastic leukemia/lymphoma; n = 537), P9425 (intermediate/high-risk Hodgkin lymphoma; n = 216), and P9426 (low-risk Hodgkin lymphoma; n = 255).
The patients in each trial were randomly assigned to receive dexrazoxane and doxorubicin or doxorubicin alone. The dose ratio for dexrazoxane to doxorubicin was 10:1 where dexrazoxane was given as IV bolus prior to doxorubicin.
Out of 507 patients (1,008 total patients) treated with dexrazoxane, 67 died (132 total deaths) during a median follow-up of 12.6 years.
In general, there was no significant mortality difference based on dexrazoxane status where the mortality with and without dexrazoxane were12.8% and 12.2%, respectively (HR=1.03; 95% CI, 0.73-1.45).
Morality was mostly associated with the original cancer with 76.5% (HR=0.90; 95% CI, 0.61-1.32) of all deaths caused by the original cancer and 13.6% (HR=1.24; 95% CI, 0.49-3.15) of all deaths caused by second cancers.
The researchers found that dexrazoxane was not associated with deaths caused by acute myeloid leukemia/myelodysplasia or cardiovascular events.
Dexrazoxane treatment did not seem to compromise overall survival among pediatric patients with leukemia or lymphoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia